Everything below concerns quality control. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
=== Withdrawal-related === Anxiety Irritability Insomnia Tremors Headaches Stomach pain Hallucinations Suicidal thoughts or urges Depression Fatigue Dizziness Sweating Confusion Potential to exacerbate existing panic disorder upon discontinuation Seizures similar to delirium tremens (with long-term use of excessive doses) Benzodiazepines such as clonazepam can be very effective in controlling status epilepticus, but, when used for longer periods of time, some potentially serious side-effects may develop, such as interference with cognitive functions and behavior. Many individuals treated on a long-term basis develop a dependence. Physiological dependence was demonstrated by flumazenil-precipitated withdrawal. Use of alcohol or other CNS depressants while taking clonazepam greatly intensifies the effects, including side effects, of the drug. A recurrence of symptoms of the underlying disease should be separated from withdrawal symptoms.
=== Sound === Hangman's Chair have generally been considered a doom metal, stoner (doom or rock), sludge, gothic metal, progressive [metal], and coldwave band. In 2018, Rich Hobson of Metal Hammer wrote: "Hangman's Chair are masters of utilising a blend of doom metal riffs and moody post-punk atmospherics". In 2022, Rich Webb of Distorted Sound Magazine noted their "shoegaze/doom metal hybrid" writing style on their albums. That same year, Angela Davey and Nick Ruskell of Kerrang! wrote that the band blends "gothic rock and epic doom metal". Also in 2022, Hobson echoed this statement, describing their music as "80s-tinged goth-doom". In 2023, the newspaper L'Alsace described the band's sound as a "melancholic doom tinged with cold wave". In 2025, David characterised the band as "navigating between doom metal and alternative rock". Journalist Pierre-Antoine Riquart wrote in 2025 that their metal sound blends with "the coldness of cold wave". "Doom, sludge, post-hardcore, it all blends together in a heavy, clammy, sticky sound", wrote Rock Sound France in 2025, also providing a general description. In 2025, Toufouti stated that the band did not like tags, though they appreciated the term "cold doom" to describe their music.
Language models with hundreds of billions of parameters, such as GPT-4 or PaLM, typically run on datacenter computers equipped with arrays of GPUs (such as NVIDIA's H100) or AI accelerator chips (such as Google's TPU). These very large models are typically accessed as cloud services over the Internet. In 2022, the United States New Export Controls on Advanced Computing and Semiconductors to China imposed restrictions on exports to China of GPU and AI accelerator chips used for generative AI. Chips such as the NVIDIA A800 and the Biren Technology BR104 were developed to meet the requirements of the sanctions. There is free software on the market which attempts to recognizing text generated by generative artificial intelligence (such as GPTZero), as well as images, audio or video coming from it. Potential mitigation strategies for detecting generative AI content include digital watermarking, content authentication, information retrieval, and machine learning classifier models. Despite claims of accuracy, both free and paid AI text detectors have frequently produced false positives, mistakenly accusing students of submitting AI-generated work.
Additional measures may include extracorporeal shockwave therapy or surgery. Between 4% and 7% of people have heel pain at any given time: about 80% are due to plantar fasciitis. Approximately 10% have the disorder at some point. It becomes more common with age. It is unclear whether one sex is more affected than the other.
=== Membrane lipid biosynthesis === There are two major classes of membrane lipids: glycerophospholipids and sphingolipids. Although many different membrane lipids are synthesized in our body, pathways share the same pattern. The first step is synthesizing the backbone (sphingosine or glycerol), the second step is the addition of fatty acids to the backbone to make phosphatidic acid. Phosphatidic acid is further modified with the attachment of different hydrophilic head groups to the backbone. Membrane lipid biosynthesis occurs in the endoplasmic reticulum membrane.
Sources: en.wikipedia.org
A second set of four single-track tunnels, the East River Tunnels, were bored from the east under the East River, linking the new station to Queens, the PRR-owned Long Island Rail Road, and Sunnyside Yard in Queens, where trains would be maintained and assembled. Construction was completed on the Hudson River tunnels on October 9, 1906, and on the East River tunnels on March 18, 1908.
Like perlite, vermiculite is a mineral that has been superheated until it has expanded into light pebbles. Vermiculite holds more water than perlite and has a natural "wicking" property that can draw water and nutrients in a passive hydroponic system. If too much water and not enough air surrounds the plants roots, it is possible to gradually lower the medium's water-retention capability by mixing in increasing quantities of perlite.
== History == Peptide amphiphiles were developed in the 1990s. They were first described by the group of Matthew Tirrell in 1995. These first reported PA molecules were composed of two domains: one of lipophilic character and another of hydrophilic properties, which allowed self-assembly into sphere-like supramolecular structures as a result of the association of the lipophilic domains away from the solvent (hydrophobic effect), which resulted in the core of the nanostructure. The hydrophilic residues become exposed to the water, giving rise to a soluble nanostructure. Work in the laboratory of Samuel I. Stupp by Hartgerink et al., in the early 2000s, reported a new type of PA that are able to self-assemble into elongated nanostructures. These novel PAs contain three regions: a hydrophobic tail, a region of beta-sheet-forming amino acids, and a charged peptide epitope designed to allow solubility of the molecule in water. In addition, the PAs may contain a targeting or signaling epitope that allows the formed nanostructures to perform a biological function, either targeting or signaling, by interacting with living systems. The self-assembly mechanism of these PAs is a combination of hydrogen-bonding between beta-sheet forming amino acids and hydrophobic collapse of the tails to yield the formation of cylindrical micelles that present the peptide epitope at extremely high density at the nanofiber surface. By changing pH or adding counterions to screen the charged surfaces of fibers, gels can be formed.
Actinic granuloma (O'Brien granuloma) Annular elastolytic giant cell granuloma (giant cell elastophagocytosis, Meischer's granuloma, Miescher's granuloma of the face) Annular sarcoidosis Benign cephalic histiocytosis (histiocytosis with intracytoplasmic worm-like bodies) Congenital self-healing reticulohistiocytosis (Hashimoto–Pritzker disease, Hashimoto–Pritzker syndrome) Erythrodermic sarcoidosis Generalized eruptive histiocytoma (eruptive histiocytoma, generalized eruptive histiocytosis) Generalized granuloma annulare Giant cell reticulohistiocytoma (solitary reticulohistiocytoma, solitary reticulohistiocytosis) Granuloma annulare in HIV disease Granuloma multiforme (Mkar disease, granuloma multiforme (Leiker)) Hand–Schüller–Christian disease Heerfordt's syndrome Hereditary progressive mucinous histiocytosis Hypopigmented sarcoidosis Ichthyosiform sarcoidosis Indeterminate cell histiocytosis Interstitial granulomatous drug reaction Langerhans cell histiocytosis (histiocytosis X) Letterer–Siwe disease Localized granuloma annulare Löfgren syndrome Lupus pernio Morpheaform sarcoidosis Mucosal sarcoidosis Multicentric reticulohistiocytosis Necrobiotic xanthogranuloma (necrobiotic xanthogranuloma with paraproteinemia) Non-X histiocytosis Papular sarcoid Papular xanthoma Patch-type granuloma annulare (macular granuloma annulare) Perforating granuloma annulare Progressive nodular histiocytosis Reticulohistiocytoma Scar sarcoid (sarcoidosis in scars) Sea-blue histiocytosis Subcutaneous granuloma annulare (deep granuloma annulare, pseudorheumatoid nodule) Subcutaneous sarcoidosis (Darier–Roussy disease, Darier–Roussy sarcoid) Systemic sarcoidosis Ulcerative sarcoidosis Xanthoma disseminatum (disseminated xanthosiderohistiocytosis, Montgomery syndrome)
=== Size and hands === A study investigating the relationship with digit ratio and found men with longer ring fingers than index fingers had longer penises, and it was the only significant predictor of both stretched and erect penis length. However, the common misconception that overall hand size predicts penis size has been widely discredited.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.